We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Controlled-Release Drug Delivery System Heals Spinal Inflammation in Mouse Model

By LabMedica International staff writers
Posted on 06 Jul 2015
Print article
Image: Scanning electron microscope (SEM) image of a field of polypyrrole nanowires (Photo courtesy of Dr. Richard Borgens, Purdue University).
Image: Scanning electron microscope (SEM) image of a field of polypyrrole nanowires (Photo courtesy of Dr. Richard Borgens, Purdue University).
A novel drug delivery system that allows controllable release of an anti-inflammatory agent directly to the site of inflammation or injury was tested successfully in a mouse model.

Investigators at Purdue University (West Lafayette, IN, USA) developed an implantable device comprising polypyrrole nanowires (PpyNWs) loaded with the anti-inflammatory corticosteroid dexamethasone. Polypyrrole is an inert and biocompatible conductive polymer material that responds to an electromagnetic field by releasing the bound drug.

The investigators lifted a one to two square millimeters patch of dexamethasone-doped PpyNWs onto a single drop of sterile water held by surface tension. The drop was deposited onto a spinal cord lesion in a transgenic mouse that produced a luminescent form of glial fibrillary acidic protein (GFAP). This protein is expressed in astrocytes that gather in high numbers at the site of central nervous system injuries where they take part in the inflammatory process and form scar tissue. In this study, the strength of the GFAP luminescent signal was a marker for degree of inflammation.

The corticosteroid dexamethasone, a powerful ameliorator of inflammation, was released from the PpyNWs by external application of an electromagnetic field for two hours per day for a week.

Results published in the May 12, 2015, online edition of the Journal of Controlled Release revealed that the GFAP signal, measured by bioluminescent imaging in the living animal, was significantly reduced in treated animals. At the end of one week, GFAP was at the edge of detection, and in some experimental animals, completely eradicated. Control animals that did not receive a patch or received a patch that did not contain dexamethasone showed no decrease in GFAP signaling.

"This method allows a very, very small dose of a drug to effectively serve as a big dose right where you need it," said senior author Dr. Richard Borgens, professor of applied neuroscience at Purdue University. "By the time the drug diffuses from the site out into the rest of the body, it is in amounts that are undetectable in the usual tests to monitor the concentration of drugs in the bloodstream."

"This tool allows us to apply drugs as needed directly to the site of injury, which could have broad medical applications," said Dr. Borgens. "The technology is in the early stages of testing, but it is our hope that this could one day be used to deliver drugs directly to spinal cord injuries, ulcerations, deep bone injuries or tumors, and avoid the terrible side effects of systemic treatment with steroids or chemotherapy."

Related Links:

Purdue University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.